With 0.84 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.17 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $4.33 whereas the lowest price it dropped to was $4.17. The 52-week range on SGHT shows that it touched its highest point at $8.45 and its lowest point at $2.03 during that stretch. It currently has a 1-year price target of $3.77. Beta for the stock currently stands at 2.48.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SGHT was up-trending over the past week, with a rise of 5.91%, but this was up by 19.11% over a month. Three-month performance surged to 56.93% while six-month performance rose 22.51%. The stock gained 18.13% in the past year, while it has lost -29.33% so far this year. A look at the trailing 12-month EPS for SGHT yields -0.98 with Next year EPS estimates of -0.90. For the next quarter, that number is -0.26. This implies an EPS growth rate of -3.28% for this year and 15.35% for next year. EPS is expected to grow by 11.93% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -13.18%.
Float and Shares Shorts:
At present, 51.38 million SGHT shares are outstanding with a float of 26.99 million shares on hand for trading. On 2025-06-13, short shares totaled 1.15 million, which was 222.00000000000003 higher than short shares on 1747267200. In addition to Mr. Paul Badawi as the firm’s Co-Founder, President, CEO & Director, Dr. David Badawi M.D. serves as its Co-Founder, CTO & Director.
Institutional Ownership:
Through their ownership of 0.50825 of SGHT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SGHT reported revenue of $17508000.0 and operating income of -$13859000.0. The EBITDA in the recently reported quarter was -$13849000.0 and diluted EPS was -$0.28.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SGHT since 5 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SGHT analysts setting a high price target of 5.0 and a low target of 3.0, the average target price over the next 12 months is 3.76667. Based on these targets, SGHT could surge 16.28% to reach the target high and fall by -30.23% to reach the target low. Reaching the average price target will result in a decline of -12.4% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.85925 being high and -$1.0502 being low. For SGHT, this leads to a yearly average estimate of -$0.96427.
